Investment Stage – Series A
Gyroscope discover, develop and deliver innovative medicines to preserve people’s sight and fight the devastating impact of blindness around the world.
Spex Capital Ltd. (SPEX), registered in England and Wales, is authorised and regulated by the Financial Conduct Authority having Firm Reference Number 963796.
©2023 · Spex Capital
©2022 · Spex Capital